Linking Ligand-Induced Alterations in Androgen Receptor Structure to Differential Gene Expression: A First Step in the Rational Design of Selective Androgen Receptor Modulators
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We have previously identified a family of novel androgen receptor (AR) ligands that, upon binding, enable AR to adopt structures distinct from that observed in the presence of canonical agonists. In this report, we describe the use of these compounds to establish a relationship between AR structure and biological activity with a view to defining a rational approach with which to identify useful selective AR modulators. To this end, we used combinatorial peptide phage display coupled with molecular dynamic structure analysis to identify the surfaces on AR that are exposed specifically in the presence of selected AR ligands. Subsequently, we used a DNA microarray analysis to demonstrate that differently conformed receptors facilitate distinct patterns of gene expression in LNCaP cells. Interestingly, we observed a complete overlap in the identity of genes expressed after treatment with mechanistically distinct AR ligands. However, it was differences in the kinetics of gene regulation that distinguished these compounds. Follow-up studies, in cell-based assays of AR action, confirmed the importance of these alterations in gene expression. Together, these studies demonstrate an important link between AR structure, gene expression, and biological outcome. This relationship provides a firm underpinning for mechanism-based screens aimed at identifying SARMs with useful clinical profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amber biomolecular simulation programs
Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20290 · Cited by 9,535 · cited 1×
“0 program (28) using the force field for protein described by Cornell et al.”
MethodSack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081565498 · Cited by 491
Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer
Langley, E., Zhou, Z.-X., & Wilson, E. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.29983 · Cited by 280
Kollman, P., Dixon, R., Cornell, W., Fox, T., Chipot, C., & Pohorille, A. (1997) · Computer Simulation of Biomolecular Systems · doi:10.1007/978-94-017-1120-3_2 · Cited by 242
Cited by
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
“789 Enzalutamide 20 (10) 4 (15) 12 (9) 3 (7) Both abiraterone and enzalutamide 46 (23) 6 (22) 27 (20) 13 (31) Neither abiraterone nor enzalutamide 55 (27) 7 (26) 42 (32) 8 (19) Interval between mCRPC and baseline biopsy on study, months 17.”
Denison, M. S., Soshilov, A. A., He, G., DeGroot, D. E., & Zhao, B. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr218 · Cited by 748
CH223191 Is a Ligand-Selective Antagonist of the Ah (Dioxin) Receptor
Zhao, B., DeGroot, D. E., Hayashi, A., He, G., & Denison, M. S. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq217 · Cited by 312
Development of selective androgen receptor modulators (SARMs)
Narayanan, R., Coss, C. C., & Dalton, J. T. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.013 · Cited by 251
“An arylproprionamide SARM mediated its actions through M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT 13 Src kinase, MEK-1/2 or MEK-3, ERK and p38 MAPK pathways, while DHT primarily affected the IP3, PLC, PI3K, PKC, ERK, and JNK pathways (90).”
InfluentialSherk, A. B., Frigo, D. E., Schnackenberg, C. G., Bray, J. D., Laping, N. J., Trizna, W., Hammond, M., Patterson, J. R., Thompson, S. K., Kazmin, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1047 · Cited by 211
“Microarray analyses done in our laboratory revealed that the SGK1 gene is regulated by androgens in the LNCaP prostate cancer cell line (5).”
Self-citationDubois, V., Laurent, M., Boonen, S., Vanderschueren, D., & Claessens, F. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0883-3 · Cited by 197
Androgen receptor coregulators: recruitment via the coactivator binding groove
van de Wijngaart, D. J., Dubbink, H. J., van Royen, M. E., Trapman, J., & Jenster, G. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.007 · Cited by 122
Chouinard, S., Barbier, O., & Bélanger, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703370200 · Cited by 109
Brooke, G. N., Parker, M. G., & Bevan, C. L. (2008) · Oncogene · doi:10.1038/sj.onc.1210955 · Cited by 79
“…studies using computer modeling of AR LBD in complex with androgen or SARMs, that were complete agonists in transcriptional assays, showed that these ligands had distinct effects on the size and shape of the coactivator cleft and the distance between the charge clamp residues (Kazmin et al., 2006).”
BackgroundNuti, R., Gargaro, M., Matino, D., Dolciami, D., Grohmann, U., Puccetti, P., Fallarino, F., & Macchiarulo, A. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5005459 · Cited by 45
Metadata
- Authors
- Kazmin, D., Prytkova, T., Cook, C. E., Wolfinger, R., Chu, T.-M., Beratan, D., Norris, J. D., Chang, C.-Y., & McDonnell, D. P.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2006-06-01
- Volume
- 20
- Issue
- 6
- Pages
- 1201-1217
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2150488741
- Cited by
- 69
- References
- 4
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.